Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19

Tao Liu*; Guang Zeng*; Huangheng Tao*; Yue Shi*; COVID-19 in Cancer Patients Research Group; Ting Wang[†]; Tongzu Liu[†]; Fangjian Guo[†]; Fuling Zhou[†]; Xinghuan Wang[†]

* Contributing equally as first authors

[†] Contributing equally as senior authors

Members of COVID-19 in Cancer Patients Research Group include: Tao Liu; Yue Shi; Hongjie Shi; Xiaoyue Zhang; Wenjun Ding; Yang Li; Xi Tong

Table of Contents

Table S1

Table S2

Page 2 Page 3

	Mean (95% Confidence Interval), Median (Interquartile Range), or n (%)		P values
	Cancer Patients	COVID-19 Patients	r values
	(n=40)	(n=1430)	
Mean Age (years)	61.0 (56.8-65.2)	58.7 (57.9-59.4)	0.3
Age group (years)			
≤70	31 (77.5)	1150 (80.4)	0.65*
>70	9 (22.5)	280 (19.6)	
Sex			
Female	22 (55.0)	723 (50.6)	0.58*
Male	18 (45.0)	707 (49.4)	
Days from symptom onset to IgM/IgG test	39(30-53)	41(33-49)	0.89
Days from symptom onset to RT-PCR test	31(27-34)	39(34-43)	0.11

Table S1. Characteristics of cancer patients with COVID-19 and other hospitalized COVID-19 patients.

Age was reported as mean (95% confidence interval). P value for the difference was from Student's t-test.

Days from symptom onset to IgM/IgG test and days from symptom onset to RT-PCR test were summarized as median

and interquartile range. P values for the differences were from Mann-Whitney tests.

* P value from the χ^2 test.

	Mean (95% CI) or n (%)		
	Positive	Negative	P Value
	(n=29)	(n=11)	
Age (years)	61.8 (56.6-67.1)	58.8 (51.3-66.4)	0.52
Age group (years)			
≤70	21 (72.4)	10 (90.9)	0.4*
>70	8 (27.6)	1 (9.1)	
Sex			
Female	16 (55.2)	6 (54.5)	0.97*
Male	13 (44.8)	5 (45.5)	
Severity of COVID-			
Moderate	20 (69.0)	9 (81.8)	0.69*
Severe	9 (31.0)	2 (18.2)	
Clinical characteris			
Progression to critical status			
No	27 (93.1)	9 (81.8)	0.3*
Yes	2 (6.9)	2 (18.2)	
ICU admission			
No	27 (93.1)	10 (90.9)	0.81*
Yes	2 (6.9)	1 (9.1)	
Death			
No	28 (96.6)	10 (90.9)	0.48*
Yes	1 (3.4)	1 (9.1)	

Table S2. Characteristics of cancer patients with COVID-19 by IgG antibodies to SARS-CoV-2 status.

Positive: cancer patients who had IgG antibodies to SARS-CoV-2.

Negative: cancer patients who did not have IgG antibodies to SARS-CoV-2.

* P value from Fisher's exact test.